As of July 3, according to the financial news app, Amgen (AMGN.US) announced that it has reached an agreement with CSL Vifor to obtain commercial rights for the innovative drug Avacopan in Asia and Latin America, including mainland China. Avacopan is a drug for treating antineutrophil cytoplasmic antibody-associated vasculitis (ANCA), which has been approved for marketing in many countries worldwide and has already been applied for marketing in China.

Public records show that Avacopan was initially discovered and developed by ChemoCentryx, which holds the commercial rights in the United States. In August 2022, Amgen announced that it would acquire ChemoCentryx for approximately $3.7 billion. Prior to this, the commercial rights for Avacopan outside the United States belonged to CSL Vifor. With this cooperation, Amgen will also have commercial rights for Avacopan in Asia and Latin America, including mainland China.

Currently, Avacopan has been approved for marketing in eight countries, including the United States, Canada, Australia, the United Kingdom, Germany, the United Arab Emirates, Japan, and South Korea. Information published on the website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) show that as early as December 2022, Avacopan capsules had already applied for marketing in China.